Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
复制标题
DOI：
10.1200/jco.1999.17.5.1356
复制
发表时间：
1999-05-01
影响因子：
45.3
通讯作者：
Francini, G
中科院分区：
文献类型：
--
作者：
Erlichman, C;O'Connell, M;Francini, G
目的：探讨氟尿嘧啶(FU)联合亚叶酸(LV)是否为B2结肠癌根治性切除术后的有效辅助治疗方案。研究对象与方法：将116例B2结肠癌患者随机分为FU+LV组或观察组，采用分层滞后模型和COX模型进行无事件(EFS)和总生存期(OS)的综合分析。结果：中位随访时间为5.75年。接受FU+LV治疗的患者的EFS或OS没有显著增加。5年危险性比EFS为0.83(90%可信区间0.72~1.07)，OS为0.86(90%可信区间0.68~1.07)。5年EFS对照组为73%，FU+LV组为76%；5年OS WAR组为80%，FU+LV组为82%。年龄增长和珍珠分化肿瘤是预后不良的重要指标(P
Purpose: The goal of this analysis was to determine whether fluorouracil (FU) and folinic acid (leucovorin, LV) is an effective adjuvant therapy for patients after potentially curative resection of colon cancer in patients with B2 tumors.Patients and Methods: One thousand sixteen patients with B2 colon cancer entered onto five separate trials were randomized to FU + LV or observation, A pooled analysis for event-free (EFS) and overall survival (OS) using a stratified lag-rank and Cox model was performed.Results: The median follow-vp duration was 5.75 years. Patients receiving FU + LV did not experience a significant increase in EFS or OS. The hazards ratio at 5 years was 0.83 (90% confidence interval, 0.72 to 1.07) for EFS and 0.86 (90% confidence interval, 0.68 to 1.07) for OS. The 5-year EFS was 73% for controls and 76% for FU + LV.The 5-year OS war 80% for controls and 82% for FU + LV. Increasing age and pearly differentiated tumors were significant indicators of poor prognosis (P